Avectas, UCD partner on cell engineering

By The Science Advisory Board staff writers

June 3, 2020 -- Avectas and the Simon Laboratory at UC Davis, California (UCD) will work together on cell-engineering technology.

UCD will characterize engineered cells with Avectas' nonviral cell-engineering platform Solupore to inform the development of next-generation cell and gene therapies.

Avectas' platform will be transferred to the Simon Laboratory where they will engineer immune cells and study the delivery of cargoes, like DNA, mRNA, and proteins. They hope the collaboration will aid in the development of new cell and gene therapies.

If you like this content, please share it with a colleague!

Related Reading

Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...

Avectas nets patent for cell engineering technology
Avectas has received a patent for its Solupore cell engineering technology.

Vycellix, Avectas partner for product development
Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.

UC Davis awarded grant for Oral CRISPR treatment
UC Davis researchers have just been awarded $1.5 million from the National Institutes of Health (NIH) to start work of a novel approach to deliver...

What Scientists Want from CRISPR Companies
Laboratories around the world are adopting the CRISPR/Cas9 genome editing technique for their research. Whether to engineer better cell lines for drug...